Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Avalyn Pharma Inc.
Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
November 25, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors
November 14, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
November 04, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree
October 08, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis
September 30, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024
September 08, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis
September 03, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
August 29, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Respiratory Society International Congress 2024
August 26, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib
August 12, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
August 05, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
August 01, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Jefferies Global Healthcare Conference
May 28, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024
May 20, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference
May 13, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
May 01, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
February 06, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference
December 06, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
November 09, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
November 06, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
October 05, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference
September 29, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
September 27, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit
September 18, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
September 12, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer
September 11, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress
September 07, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
August 07, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.